Literature DB >> 24401751

Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension.

Eugenia Gkaliagkousi1, Eleni Gavriilaki, Barbara Nikolaidou, Fani Chatzopoulou, Panagiota Anyfanti, Areti Triantafyllou, Konstantinos Petidis, Chrysanthos Zamboulis, Stella Douma.   

Abstract

BACKGROUND: Cardiotrophin 1 (CT-1) is an interleukin 6-related cytokine recently implicated in cardiac hypertrophy and vascular damage in essential hypertension (EH). We aimed first to determine CT-1 levels in naive, untreated patients with grade I EH (UH) as compared with normotensive (NT) individuals and, second, to investigate a possible association of CT-1 levels with indices of arterial stiffness.
METHODS: We enrolled 45 consecutive untreated patients recently diagnosed with grade I EH by means of office and ambulatory blood pressure (BP) measurements and 25 age- and sex-matched NT subjects. CT-1 levels were measured with a commercially available enzyme-linked immunosorbent assay kit, and indices of arterial stiffness were determined by applanation tonometry.
RESULTS: CT-1 levels were significantly elevated in UH patients compared with NT subjects (P < 0.001). Furthermore, CT-1 levels correlated positively with office, ambulatory and central BP. A significant bivariable correlation was also found between CT-1 levels and pulse wave velocity (P = 0.02). In the multivariable analysis, central systolic and diastolic BP proved the only significant predictors of CT-1 levels after controlling for other related factors.
CONCLUSIONS: To our knowledge, this is the first study that correlates CT-1 levels with ambulatory and central BP, as well as with pulse wave velocity in patients with essential hypertension. Thus, studying the effects of CT-1 in the cardiovascular system in patients with EH represents a promising area of investigation in the future.

Entities:  

Keywords:  arterial stiffness; blood pressure; cardiotrophin-1; central blood pressure; essential hypertension; hypertension.

Mesh:

Substances:

Year:  2014        PMID: 24401751     DOI: 10.1093/ajh/hpt238

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

Review 1.  Clinical Significance of Endothelial Dysfunction in Essential Hypertension.

Authors:  Eugenia Gkaliagkousi; Eleni Gavriilaki; Areti Triantafyllou; Stella Douma
Journal:  Curr Hypertens Rep       Date:  2015-11       Impact factor: 5.369

Review 2.  Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis.

Authors:  Kangxing Song; Shuxia Wang; Bihui Huang; Amelia Luciano; Roshni Srivastava; Arya Mani
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-07-23       Impact factor: 3.738

3.  Reply to: Seeing the forest, but not the trees: pertinent considerations for examining acute changes in pulse wave velocity in response to pharmaceutical interventions and exercise.

Authors:  Eugenia Gkaliagkousi; Eleni Gavriilaki; Stella Douma
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-08-07       Impact factor: 3.738

4.  Exercise-induced pulse wave velocity changes in untreated patients with essential hypertension: the effect of an angiotensin receptor antagonist.

Authors:  Eugenia Gkaliagkousi; Eleni Gavriilaki; Barbara Nikolaidou; George Triantafyllou; Stella Douma
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-05-22       Impact factor: 3.738

Review 5.  The Role of Interleukin-6 Family Members in Cardiovascular Diseases.

Authors:  Yongqi Feng; Di Ye; Zhen Wang; Heng Pan; Xiyi Lu; Menglong Wang; Yao Xu; Junping Yu; Jishou Zhang; Mengmeng Zhao; Shuwan Xu; Wei Pan; Zheng Yin; Jing Ye; Jun Wan
Journal:  Front Cardiovasc Med       Date:  2022-03-23

6.  Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk.

Authors:  Luis Gamella-Pozuelo; Isabel Fuentes-Calvo; Manuel A Gómez-Marcos; José I Recio-Rodriguez; Cristina Agudo-Conde; José L Fernández-Martín; Jorge B Cannata-Andía; José M López-Novoa; Luis García-Ortiz; Carlos Martínez-Salgado
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.